New York, May 28, 2026, 13:02 (EDT)
- YD Bio traded at $3.60 at 12:50 p.m. EDT, down 8.6%, while the Nasdaq market was open.
- A May 26 SEC amendment updated a resale and warrant-share registration; it did not register additional securities.
- The move stood out against a firmer biotech tape, with XBI, Guardant Health and Natera all higher.
YD Bio Ltd shares fell sharply on Thursday, extending a three-session slide that has pushed the Nasdaq-listed biotechnology stock about 24% below last Friday’s close.
The shares were quoted at $3.60 at 12:50 p.m. EDT, down 8.6% on the day and near the low end of their recent range. The stock closed at $4.75 on May 22, fell on May 26 and May 27, and was trading lower again on Thursday.
The pressure matters now because it followed YD Bio’s May 26 post-effective amendment to a Form F-1 registration statement. The filing refreshed a prospectus tied to shares issuable from warrants and shares held by selling shareholders, language that can draw close attention in thinly traded small-cap stocks.
The filing showed the prospectus covers 11.4 million ordinary shares issuable on public warrants, 58.6 million ordinary shares held by selling shareholders, and 3.1 million ordinary shares issuable on private warrants. A warrant is a contract that gives its holder the right to buy shares at a set price. YD Bio said no extra securities were being registered in the amendment.
The company also said it would not receive proceeds from shares sold by selling shareholders. It could receive cash if warrants are exercised, though the warrants carry an $11.50 exercise price, well above Thursday’s quoted share price, making them “out of the money” — market shorthand for an exercise price above the current stock price.
Trading remained light. Robinhood’s stock snapshot listed volume at 5,360 shares against average daily volume of 9,090, and put the stock’s 52-week range at $3.65 to $25.00.
YD Bio’s weakness contrasted with a stronger market for some larger diagnostics and biotech names. The SPDR S&P Biotech ETF was up 0.9%, Guardant Health rose 1.3%, and Natera gained 1.4%, according to market data.
The company says it is building a platform across regulated diagnostics, clinical services and healthcare commercialization, including DNA methylation-based oncology testing. DNA methylation refers to chemical changes on DNA that can be used as signals in some cancer-detection tests.
YD Bio’s latest full-year results showed 2025 revenue rose 17% to $596,817, while its net loss widened to $8.31 million from $1.41 million. Chairman and CEO Dr. Ethan Shen said in April that the company ended 2025 “well-capitalized” with about $6.0 million in cash and cash equivalents.
But the downside case is clear. YD Bio warned in its annual report that substantial doubt exists about its ability to continue as a going concern, and said it may need more financing to implement its business plan. That raises the risk of dilution, meaning existing shareholders could own a smaller percentage of the company if new equity or equity-linked securities are issued.
The next test is whether YD Bio can turn its regulatory and diagnostics plans into revenue fast enough to offset investor concern over liquidity, possible share supply and a still-small sales base. For now, the tape is doing the talking.
